Controlled release formulation of divalproex sodium
US6528091B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 10, 2002 |
| Grant date | Mar 4, 2003 |
| Priority date | — |
| Expiry date | May 10, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A controlled release tablet formulation which permits once daily dosing in the treatment of epilepsy comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weight percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent silicon dioxide having an average particle size ranging between about 1 micron and about 10 microns; all weight percentages based upon the total weight of the tablet dosage form. Also disclosed are pre-tableting granular formulations, methods of making the granular formulations and tablets, and a method of treating epilepsy employing the controlled release tablet formulations of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.